1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Generic Industry’s Future May Include A Role In The Gene Therapy Space

 
• By Derrick Gingery

Trade association’s CEO says a new strategic planning initiative will consider among other things how gene therapy could fit into the generic industry business model.

Gene Therapy
Could the generic industry target the gene therapy market next? • Source: Alamy

Personalized medicine does not immediately fit into the generic industry model of high-volume and low prices, given its goal of providing tailored treatments for a single patient. Still, Association for Accessible Medicines president and CEO Dan Leonard wants the industry to consider its options.

During his 27 May State of AAM address as part of the generics trade association’s annual meeting, Leonard announced the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.